Article
Following the Money: Rx Revenues Underpin Community Oncology Business Models
Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.
Read MoreThe Latest
Article
IDN Financial Incentives: Impact on Treatment Prices?
Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma Bijesse
Article
Provider Economics Drive Oncologist Consolidation
Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Taylor Crutison
Article
An Update on What You Need to Know About Pathways
Welcome to the February 2024 edition of our Monthly Insight Series, featuring key findings from our recent column in the Journal of Clinical Pathways. The column was the first in a series on oncologists' awareness and use of pathways.
Lee Blansett
Article
Oncology Insights: Clinical Decision Support
Welcome to the January 2024 edition of our Monthly Insight Series. This month we are discussing clinical decision support systems in oncology.
Chris Van Denburg
Article
Oncology Insights: Notable Quotes from Key Decision Makers
Welcome to the December 2023 edition of our Monthly Insight Series. This month we are discussing standout quotes from discussions we had this year, and how they impact our key customer segments.
Taylor Crutison, Chris Van Denburg, Cindy Chen
Article
What's Going On with Oncology Pathways? Here's What You Need to Know
Welcome to the November 2023 edition of our Monthly Insight Series. This month we are highlighting a few key findings from our recently published report on Oncology Clinical Pathways.
Lee Blansett
Article
Payer Insight: It’s NOT All About Drugs
Welcome to the October 2023 edition of our Monthly Insight Series. This month we highlight a specific finding from our 2023 Payer Annual Oncology Trend Report that was just released in September: Payers’ top cancer cost targets.
Chris Van Denburg
Article
Summer 2023 Recap: Here’s What You Missed From MAI
Welcome to the September 2023 edition of our Monthly Insight Series. This month we are giving a quick overview of the various reports we’ve released to our clients this summer—it’s been a busy one!
Taylor Crutison
Article
Oncology Network Aggregators: Gaining Popularity?
Welcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.
Taylor Crutison
Article
The Enhancing Oncology Model: What Lies Ahead for Participants?
CMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.
Taylor Crutison
Article
IDN Pharmacy Performance Metrics: Opportunities for Manufacturers to Engage
Welcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.
Cindy Chen
Article
Clinical Pathways Impact on Treatment Selection
As more providers explore clinical pathways as a tool for increasing clinical consistency and quality, we need to examine adoption benefits and challenges, provider compliance, and potential access risks for manufacturers.
Lee Blansett
Article
CONFLICTED: Payer Pathways vs Their Own Coverage Policies
Welcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.
Chris Van Denburg
Article
Medicare Advantage Growth Will Bring Changes for Cancer Drug Manufacturers
Changes to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.
Lee Blansett
Article
Pharmacists’ Shifting Meeting Preferences
Welcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.
Cindy Chen
Article
Humana Quits Commercial
Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.
Chris Van Denburg
Article
HMP Global Market Access Insights’ 2023 Research Year
We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.
Lee Blansett
Article
Community Oncology Providers and Value-based Care: Here’s What You Should Know
Welcome to the February 2023 edition of our Monthly Insight Series. This month we discuss how community oncology providers are engaging in value-based care.
Taylor Crutison, Lee Blansett
Article
Oncology Value-based Care & Private Payers: What Exactly Is Going On?
Welcome to the January 2023 edition of our Monthly Insight Series. This month we discuss value-based care in oncology from a private-payer perspective.
Chris Van Denburg, Lee Blansett
Article
The Inflation Reduction Act: Here's What You Need to Know
Welcome to the December 2022 edition of our Monthly Insight Series. This month we highlight the Inflation Reduction Act of 2022 (IRA).
Taylor Crutison, Cindy Chen, Lee Blansett
Article
In Case You Missed It: “Perspectives on Vertical Payers” Is Out Now!
Welcome to the October 2022 edition of our Monthly Insight Series. This month we discuss our new Perspectives on Vertical Payers report.
Chris Van Denburg
Article
Payer or Provider: Two Sides of the Same Coin?
Welcome to the September 2022 edition of our Monthly Insight Series. This month we discuss our inaugural Payer Report Series, which is launching soon.
Chris Van Denburg
Article
IDN Readout Roundup: Controls, Controls, and More Controls
Welcome to the June 2022 edition of our Monthly Insight Series. This month we highlight several queries that have generated lively discussions thus far.
Cindy Chen
Article
Routine Access for Cancer Drugs in IDNs: More Than Just a Click Away
Welcome to the May edition of our Monthly Insight Series. MAI conducts a Brand Survey as part of our annual IDN Trend Survey. For 2022, we continued this tradition as we set out to understand the prescribing burden for IDN oncologists.
Cindy Chen
Article
Moving Forward: Engaging With Oncology Pharmacy Providers
As we busily analyze field data collected from our annual IDN survey, we would like to offer a sneak peek at how oncology pharmacists want to engage with manufacturers in 2022 and beyond.
Cindy Chen
Article
Understanding HMP Global Market Access Insights' New Payer Report Series
Welcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.
Chris Van Denburg